Vanguard discloses 4.73% Avita Medical (RCEL) stake in 13G/A
Rhea-AI Filing Summary
The Vanguard Group filed an amended Schedule 13G reporting its beneficial ownership of Avita Medical Inc common stock. Vanguard reports beneficially owning 1,444,579 shares, representing 4.73% of the outstanding common stock, with shared voting power over 190,616 shares and shared dispositive power over all 1,444,579 shares.
Vanguard indicates it holds the securities in the ordinary course of business and not to change or influence control of Avita Medical. The filing notes an internal realignment on January 12, 2026, after which certain Vanguard subsidiaries or business divisions are expected to report beneficial ownership separately.
Positive
- None.
Negative
- None.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What does The Vanguard Group’s Schedule 13G/A for RCEL report?
The Schedule 13G/A shows The Vanguard Group beneficially owns 1,444,579 Avita Medical shares, or 4.73% of the common stock. Vanguard reports shared voting power over 190,616 shares and shared dispositive power over all 1,444,579 shares, held in the ordinary course of business.
Does Vanguard intend to influence control of Avita Medical (RCEL)?
Vanguard certifies the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Avita Medical. The filing also notes they are not held in connection with any control-related transaction, aside from specified proxy nomination activities.
What change did Vanguard disclose about its organizational structure?
Vanguard explains that on January 12, 2026, it completed an internal realignment. After this, The Vanguard Group, Inc. no longer performs portfolio management or proxy voting, and certain subsidiaries or business divisions are expected to report beneficial ownership separately on a disaggregated basis.
Why does Vanguard file on Schedule 13G for Avita Medical (RCEL)?
Vanguard files on Schedule 13G because it characterizes itself as holding Avita Medical shares in the ordinary course of business without a control intent. Schedule 13G is a short-form ownership report typically used by institutional investors that are passive with respect to issuer control.